IP Library Granted Patent US 9,873,912
Granted Patent B2
US 9,873,912 · App. 15/065,739 · Granted Jan 23, 2018

Compositions and processes for improved mass spectrometry analysis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,873,912
App. No.
15/065,739
Filed
Mar 9, 2016
Granted
Jan 23, 2018
Kind
B2
Art Unit
1634
USPC
436/175
Abstract

The invention provides a novel additive for improved analysis by mass spectrometry. More specifically, ascorbic acid has been found to reduce or eliminate the presence of adducts commonly present in mass spectra. The improved processes and compositions of the invention allow for increased accuracy, sensitivity and throughput for samples analyzed by mass spectrometry.

Claims (20)

1. A matrix material for mass spectrometry, comprising:

an adduct-reducing additive comprising ascorbic acid or a salt, tautomer or analog thereof; and

a matrix comprising one or more of 3-hydroxypicolinic acid, di-ammoniumcitrate, 2,5- dihydroxybenzoic acid, Alpha-cyano-4-hydroxycinnamic acid, 2,4,6-trihydroxyacetophenone, T-2-(3-(4-t-Butyl-phenyl)-2-methyl-2-propenylidene)malononitrile, dithranol, sinapic acid, trans-3-indoleacrylic acid, or 2-(4-hydroxyphenylazo)benzoic acid, wherein the analog of ascorbic acid comprises the formula:

wherein:

R 1 and R 2 independently are OH, halogen, R 3 , OR 3 , azido, cyano, CH 2 R 3 , CHR 3 R 4 , SR 3 , NR 3 R 4 ; and

R 3 and R 4 independently are H, alkyl, acetylene or cyano, or an optionally substituted aryl carbocyclic ring, aryl heterocyclic ring, non-aryl carbocyclic ring or non-aryl heterocyclic ring.

2. The matrix material of claim 1 , wherein-the adduct-reducing additive is in an amount of between 99% to 1% by weight of the overall weight of the matrix material.

3. The matrix material of claim 1 , wherein the adduct-reducing additive comprises ascorbic acid.

4. The matrix material of claim 1 , wherein the matrix comprises 3-hydroxypicolinic acid.

5. The matrix material of claim 1 , wherein the matrix comprises di-ammonium citrate.

6. The matrix material of claim 3 , further comprising ammonium oxalate.

7. The matrix material of claim 4 , further comprising ammonium oxalate.

8. The matrix material of claim 1 , wherein the concentration of the adduct-reducing additive is about 5 mM to about 50 mM.

9. A substrate, comprising a support that includes an array of spots, wherein one or more of the spots comprises the matrix material of claim 1 .

10. The substrate of claim 9 , wherein the adduct-reducing additive comprises ascorbic acid.

11. The substrate of claim 9 , wherein the matrix comprises 3-hydroxypicolinic acid.

12. The substrate of claim 11 , wherein the matrix material further comprises ammonium oxalate.

13. The substrate of claim 9 , wherein the concentration of the adduct-reducing additive is about 5 mM to about 50 mM.

14. The substrate of claim 9 , wherein the one or more spots include an analyte.

15. The substrate of claim 14 , wherein the analyte is a nucleic acid.

Assignments (5)
SECURITY INTEREST Recorded Dec 10, 2021
From: AGENA BIOSCIENCE, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058358/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2019
From: BECKER, THOMAS
To: SEQUENOM, INC.
Reel/Frame 048637/0397 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: BECKER, THOMAS
To: AGENA BIOSCIENCE, INC.
Reel/Frame 048626/0797 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: SEQUENOM, INC.
To: AGENA BIOSCIENCE, INC.
Reel/Frame 048627/0016 →
CHANGE OF NAME Recorded Mar 18, 2019
From: BIOSCIENCES ACQUISITION COMPANY
To: AGENA BIOSCIENCE, INC.
Reel/Frame 048629/0775 →